## Attachment 2: Technology End-Users Interview Guide

OMB No.: 0925-0720

Expiration Date: 05/31/2016

Collection of this information is authorized by The Public Health Service Act, Section 410 (42 USC 285). Rights of participants are protected by The Privacy Act of 1974. Participation is voluntary, and there are no penalties for not participating or withdrawing from the study at any time. The information collected in this study will be kept private to the extent provided by law. Names and other identifiers will not appear in any report of the study. Information provided will be combined for all participants and reported as summaries. You are being contacted by telephone to complete this interview as part of a full-scale evaluation of the IMAT Program.

Public reporting burden for this collection of information is estimated to average 30 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. **An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number.** Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to: NIH, Project Clearance Branch, 6705 Rockledge Drive, MSC 7974, Bethesda, MD 20892-7974, ATTN: PRA (0925-0720). Do not return the completed form to this address.

Hello, is this is Dr. \_\_\_\_\_\_\_? My name is \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_, and I’m a member of the project team working with NCI to evaluate the Innovative Molecular Analysis Technologies Program. As you may know, NCI is conducting a full-scale evaluation of the IMAT Program. I work for \_\_\_\_\_\_\_\_\_, a research and evaluation firm in \_\_\_\_\_\_\_\_\_\_, charged with the task of conducting this evaluation. We greatly appreciate your willingness to answer a few questions about the IMAT Program. As you may or may not know, the IMAT program provides early stage support for innovative technologies that contribute to the advancement of cancer relevant research. You have been identified as someone familiar with a relevant field of research for which one or several of these technologies may have offered significant contributions to advancing such research. In particular, the \_\_\_\_\_\_\_ is one of these innovative technologies supported by IMAT program grants. I want to assure you that your participation is voluntary and that your responses will be kept private to the extent provided by law. We would like you to be totally candid. We will take careful precautions to ensure that your name cannot be associated with your responses. We expect our discussion to take about \_\_\_\_ minutes. Do you wish to proceed at this time?

If yes: Good. We realize that your time is valuable, so let’s get started.

If no: Would you like to schedule another time for this discussion? (Try to schedule another time and thank the respondent for his or her willingness to participate.)

* Have or are you using the technology to do basic research? Are you using the technology in your practice?
* To what extent is the technology critical in your research/practice?
* Are you using the technology to develop other derivative technologies?
* Are you receiving funding to do this?
* What agencies are funding this activity?
* Have you published any results stemming from this using this technology?
* Have you made any presentations at conferences/seminars on result stemming from the use of this technology?
* To what extent has this technology enabled your research in terms of pursuing new ideas? In terms of producing results more quickly or more accurately?

*If you have any questions, feel free to contact Tony Dickherber with any additional questions at 301-480-2889 or by email at dickherberaj@mail.nih.gov.*